When transgenes shape immunity: cancer immune-gene therapy
- PMID: 22736622
- DOI: 10.1002/jgm.2645
When transgenes shape immunity: cancer immune-gene therapy
Comment on
-
CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic.J Gene Med. 2012 Jun;14(6):416-27. doi: 10.1002/jgm.1648. J Gene Med. 2012. PMID: 22228547 Free PMC article. Review.
-
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.J Gene Med. 2012 Jun;14(6):405-15. doi: 10.1002/jgm.2604. J Gene Med. 2012. PMID: 22262649 Free PMC article. Review.
-
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.J Gene Med. 2012 Jun;14(6):428-39. doi: 10.1002/jgm.2605. J Gene Med. 2012. PMID: 22262664
-
Cancer therapy with genetically-modified T cells for the treatment of melanoma.J Gene Med. 2012 Jun;14(6):400-4. doi: 10.1002/jgm.2636. J Gene Med. 2012. PMID: 22610729 Review.
-
Challenges in T cell receptor gene therapy.J Gene Med. 2012 Jun;14(6):386-99. doi: 10.1002/jgm.2637. J Gene Med. 2012. PMID: 22610778 Review.
-
Long-term follow-up of cancer patients treated with gene therapy medicinal products.J Gene Med. 2012 Jun;14(6):440-2. doi: 10.1002/jgm.2638. J Gene Med. 2012. PMID: 22639413 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical